Tempus AI Presents AI-Driven Oncology Advancements at ESMO Congress 2024
Key Insights
Tempus AI will present four abstracts at the ESMO Congress 2024, showcasing advancements in AI-driven precision medicine for oncology.
An oral presentation will highlight Tempus' TIME initiative, which streamlines patient screening and clinical trial matching using AI, improving enrollment.
A poster presentation will explore ctDNA monitoring in TKI-treated patients, suggesting its potential for assessing treatment response beyond VAF monitoring.
Tempus AI (NASDAQ: TEM) is set to present four abstracts at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, from September 13-17. The presentations will cover various applications of artificial intelligence (AI) and comprehensive genomic profiling in oncology, aiming to improve patient outcomes and advance precision medicine.
AI-Driven Clinical Trial Program
An oral presentation (#CN13) will detail the impact of Tempus' AI Clinical Trial Program on screening, matching, and enrollment of patients over a six-month period. This initiative, conducted in collaboration with Cleveland Clinic, demonstrates how AI can streamline patient screening and accelerate clinical trial activation. The TIME initiative achieved an average of more than one consent per day over six months, highlighting the potential of AI to enhance patient access to clinical trials.
Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus, stated, "ESMO provides a great platform to share our recent research and advancements with the global oncology community, foster further collaboration, and drive forward the mission of improving patient outcomes. At Tempus, we are committed to leveraging AI and data to transform cancer care and research, and this is a great opportunity to showcase the impact of our innovative approaches to both."
ctDNA Monitoring in TKI-Treated Patients
A poster presentation (#113P) will evaluate the use of circulating tumor DNA (ctDNA) for monitoring treatment response in advanced solid tumor patients treated with tyrosine kinase inhibitors (TKIs (search)). The study, utilizing the Tempus xM ctDNA assay, classified patients as molecular responders (MRs) or non-responders (nMRs) based on changes in ctDNA tumor fraction (TF). Results showed that molecular responders had longer overall survival compared to non-responders. Among patients with decreasing variant allele frequencies (VAF, n=21), those who were MRs (n=12) had significantly longer survival compared to nMRs (n=9). The study suggests that ctDNA TF monitoring may be a valuable tool for monitoring response to TKI therapy beyond targeted VAF monitoring alone.
Genomic Profiling and Targeted Therapy in NSCLC
Another poster presentation (#79P) will assess adherence to guideline-recommended targeted therapy recommendations and the time from genomic sequencing to the initiation of targeted treatment in a diverse, real-world dataset of advanced non-small cell lung cancer (NSCLC (search)) patients. The findings indicate that most oncologists utilized comprehensive genomic profiling (CGP) to identify and treat patients with guideline-recommended, variant-matched targeted therapy, with adherence rates varying according to the variant. Notably, even patients who received CGP results prior to FDA approval of novel therapies received matched therapy once they were included in guidelines.
Impact of RAS and BRAF Mutations in Colorectal Cancer
Poster presentation (#580P) aims to understand the impact of RAS (search) and BRAF (search) mutations on prognosis and treatment effects in MSI/dMMR patients in both localized and metastatic settings. These data suggest that MSI/dMMR colorectal cancers (search) (CRC) with RAS mutations are less immunogenic and exhibit a lower tumor inflammatory profile in the tumor immune microenvironment (TIME) compared to those with RAS wild-type (RASwt) or BRAF V600E mutations. Further analysis and validation are required to confirm these findings.